SCHEMBL9908423

SCHEMBL9908423

OCCCC1CC2CCC1C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 2/20 0.34
POLB P06746 1/20 0.33
OPRK1 P41145 4/20 0.33
P2RX7 Q99572 1/20 0.31
HPGD P15428 1/20 0.31
EPHX1 P07099 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19746512 0.86 MEN1 (0.41) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL3316247 0.86 MEN1 (0.41) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL3447574 0.86 MEN1 (0.39) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL25233759 0.81 MEN1 (0.41) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL7129953 0.78 CYP1A2 (0.37) MEN1NPC1RAB9AKMT2AOPRK1
SCHEMBL31033440 0.78 MEN1 (0.35) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL8740469 0.78 MEN1 (0.36) MEN1NPC1RAB9AKMT2APOLB
SCHEMBL11604734 0.78 MEN1 (0.42) MEN1NPC1RAB9AKMT2AEPHX2
SCHEMBL3332075 0.77
SCHEMBL3332078 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078079-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES OSMO LABS PBC (US) 2026-03-19 US disclosed
CN-111148739-B Cyclic peptide antibiotics 豪夫迈·罗氏有限公司 2025-06-03 CN disclosed
US-20230192575-A1 TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME SK CHEMICALS CO., LTD. (KR) 2023-06-22 US disclosed
US-20230192577-A1 TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME SK CHEMICALS CO., LTD. (KR) 2023-06-22 US disclosed
CN-111148739-A Cyclopeptide antibiotics 豪夫迈·罗氏有限公司 2020-05-12 CN disclosed
US-9448482-B2 Pattern forming method, resist pattern formed by the method, method for manufacturing electronic device using the same, and electronic device FUJIFILM CORPORATION (JP) 2016-09-20 US disclosed
US-20150253673-A1 PATTERN FORMING METHOD, RESIST PATTERN FORMED BY THE METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2015-09-10 US disclosed
US-8198016-B2 Patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20090286188-A1 Patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192577-A1 TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME DHCR7, TET1, TET3 MEN1 2936/4885NPC1 1851/4885RAB9A 2270/4885
US-20230192575-A1 TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME DHCR7, DHCR24, CYP19A1 MEN1 1754/4885NPC1 1888/4885RAB9A 3591/4885
US-20260078079-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES CBR1, CBR3, TAS2R1 MEN1 3787/4885NPC1 1366/4885RAB9A 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.